Abiopharma

🔍 Morgan Amanda Michelle (Executive)

Company: Lantheus Holdings, Inc. (LNTH)

Report Date: 2026-03-05

Detailed Transactions and Holdings:

• Acquired 26,208 shares of Common Stock (Direct)
  Date: 2026-03-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 64,748.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 595 shares of Common Stock at $76.31 per share (Direct)
  Date: 2026-03-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 64,153.00 | transaction_form_type: 4

Footnotes:

• F1: Consists of 13,104 restricted stock units that vest in equal installments over a three-year period and 13,104 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award; however, the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.